ArticleBMC ophthalmology2025
Severe retinopathy induced by low-dose tamoxifen: a 10-month follow-up analysis based on multimodal imaging.
Article in BMC ophthalmology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundTamoxifen retinopathy (TAM-R) typically occurs with prolonged and high-dose administration. This study presents an uncommon instance of severe TAM-R following 3.75 years of low-dose tamoxifen (10 mg/day) treatment, totaling 450 mg cumulatively. CASE REPORT: A 35-year-old female with obesity (BMI 47.86 kg/m²) presented with bilateral vision loss. Multimodal imaging (OCT/OCTA/FFA/FAF) revealed retinal crystal deposition, macular pseudocyst, ellipsoid layer rupture, and deep capillary plexus loss. Despite discontinuation of medication, visual acuity remained poor (BCVA of 20/125 in the right eye and 20/667 in the left eye). At the 10-month follow-up, there was partial structural improvement, yet ellipsoid layer impairment persisted.
conclusionThis case challenges traditional TAM-R dosage thresholds, suggesting obesity may exacerbate toxicity. Baseline OCTA vascular markers correlate with irreversible visual impairment, offering novel insights for prognostic evaluation.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.